Cargando…

Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs

Blockchain is a novel data architecture characterized by a chronological sequence of blocks in a decentralized manner. We aimed to evaluate the real‐world feasibility of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter trial. The study consisted of three visits...

Descripción completa

Detalles Bibliográficos
Autores principales: Huh, Ki Young, Moon, Seol Ju, Jeong, Sang‐un, Kim, Min‐Ji, Yang, Wooseok, Jeong, Myeonggyu, Kim, Min‐Gul, Lee, SeungHwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099134/
https://www.ncbi.nlm.nih.gov/pubmed/35157788
http://dx.doi.org/10.1111/cts.13246
_version_ 1784706536328658944
author Huh, Ki Young
Moon, Seol Ju
Jeong, Sang‐un
Kim, Min‐Ji
Yang, Wooseok
Jeong, Myeonggyu
Kim, Min‐Gul
Lee, SeungHwan
author_facet Huh, Ki Young
Moon, Seol Ju
Jeong, Sang‐un
Kim, Min‐Ji
Yang, Wooseok
Jeong, Myeonggyu
Kim, Min‐Gul
Lee, SeungHwan
author_sort Huh, Ki Young
collection PubMed
description Blockchain is a novel data architecture characterized by a chronological sequence of blocks in a decentralized manner. We aimed to evaluate the real‐world feasibility of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter trial. The study consisted of three visits (i.e., screening and 2 follow‐up visits) with a 2‐week interval. Each subject was required to report the self‐measured body temperatures and take a virtual investigational drug by entering the unique drug code on the application. To simulate real‐world study settings, two major (i.e., changes in the schedule of body temperature measurement) and three minor protocol amendments (i.e., nonsignificant changes without any changes in the procedures) were set. Overall study completion rates, proportion of consent, and response time to each protocol amendment and adherence were evaluated. A total of 60 subjects (30 in each center) were enrolled in two study centers. All subjects completed the study, and the overall proportion of consent to each protocol amendment was 95.7 ± 13.7% (mean ± SD), with a median response time of 0.2 h. Overall, subjects took 90.8% ± 19.2% of the total drug, whereas compliance with the schedule was 69.1% ± 27.0%. Subjects reported 96.7% ± 4.2% of the total body temperature measurements whereas the adherence to the schedule was 59.0% ± 25.0%, which remarkably decreased after major protocol amendments. In conclusion, we evaluated a blockchain‐based dynamic consent platform in real clinical trial settings. The results suggested that major changes should be avoided unless subjects’ proper understanding is warranted.
format Online
Article
Text
id pubmed-9099134
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90991342022-05-18 Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs Huh, Ki Young Moon, Seol Ju Jeong, Sang‐un Kim, Min‐Ji Yang, Wooseok Jeong, Myeonggyu Kim, Min‐Gul Lee, SeungHwan Clin Transl Sci Research Blockchain is a novel data architecture characterized by a chronological sequence of blocks in a decentralized manner. We aimed to evaluate the real‐world feasibility of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter trial. The study consisted of three visits (i.e., screening and 2 follow‐up visits) with a 2‐week interval. Each subject was required to report the self‐measured body temperatures and take a virtual investigational drug by entering the unique drug code on the application. To simulate real‐world study settings, two major (i.e., changes in the schedule of body temperature measurement) and three minor protocol amendments (i.e., nonsignificant changes without any changes in the procedures) were set. Overall study completion rates, proportion of consent, and response time to each protocol amendment and adherence were evaluated. A total of 60 subjects (30 in each center) were enrolled in two study centers. All subjects completed the study, and the overall proportion of consent to each protocol amendment was 95.7 ± 13.7% (mean ± SD), with a median response time of 0.2 h. Overall, subjects took 90.8% ± 19.2% of the total drug, whereas compliance with the schedule was 69.1% ± 27.0%. Subjects reported 96.7% ± 4.2% of the total body temperature measurements whereas the adherence to the schedule was 59.0% ± 25.0%, which remarkably decreased after major protocol amendments. In conclusion, we evaluated a blockchain‐based dynamic consent platform in real clinical trial settings. The results suggested that major changes should be avoided unless subjects’ proper understanding is warranted. John Wiley and Sons Inc. 2022-02-17 2022-05 /pmc/articles/PMC9099134/ /pubmed/35157788 http://dx.doi.org/10.1111/cts.13246 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Huh, Ki Young
Moon, Seol Ju
Jeong, Sang‐un
Kim, Min‐Ji
Yang, Wooseok
Jeong, Myeonggyu
Kim, Min‐Gul
Lee, SeungHwan
Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs
title Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs
title_full Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs
title_fullStr Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs
title_full_unstemmed Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs
title_short Evaluation of a blockchain‐based dynamic consent platform (METORY) in a decentralized and multicenter clinical trial using virtual drugs
title_sort evaluation of a blockchain‐based dynamic consent platform (metory) in a decentralized and multicenter clinical trial using virtual drugs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099134/
https://www.ncbi.nlm.nih.gov/pubmed/35157788
http://dx.doi.org/10.1111/cts.13246
work_keys_str_mv AT huhkiyoung evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs
AT moonseolju evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs
AT jeongsangun evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs
AT kimminji evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs
AT yangwooseok evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs
AT jeongmyeonggyu evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs
AT kimmingul evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs
AT leeseunghwan evaluationofablockchainbaseddynamicconsentplatformmetoryinadecentralizedandmulticenterclinicaltrialusingvirtualdrugs